Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma

Journal of Clinical Oncology

Volumn 18, Issue 13, 2000, Pages 2567-2575

  Grupp, Stephan A ^a   Stern, Julie W ^a   Bunin, Nancy ^a   Nancarrow, Cheryl ^a   Ross, Amy A ^a   Mogul, Mark ^a   Adams, Roberta ^a   Grier, Holcombe E ^a   Gorlin, Jed B ^a   Shamberger, Robert ^a   Marcus, Karen ^a   Neuberg, Donna ^a   Weinstein, Howard J ^a   Diller, Lisa ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; VINCRISTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; NEUROBLASTOMA; PANCYTOPENIA; PRESCHOOL CHILD; PRIORITY JOURNAL;

EID: 0033917099     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.13.2567     Document Type: Article

References (37)

1. Cheung NV, Heller G: Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 9:1050-1058, 1991
2. Matthay KK: Impact of myeloablative therapy with bone marrow transplantation in advanced neuroblastoma. Bone Marrow Transplant 18:S21-S24, 1996
3. Matthay KK, Villablanca JG, Seeger RC, et al: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 341:1165-1173, 1999
4. Philip T, Ladenstein R, Zucker JM, et al: Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma: The LMCE2 study. Br J Cancer 67:119-127, 1993
5. Broun ER, Sridhara R, Sledge GW, et al: Tandem autotransplantation for the treatment of metastatic breast cancer. J Clin Oncol 13:2050-2055, 1995
6. Lotz JP, Bouleuc C, Andre T, et al: Tandem high-dose chemotherapy with ifosfamide, carboplatin, and teniposide with autologous bone marrow transplantation for the treatment of poor prognosis common epithelial ovarian carcinoma. Cancer 77:2250-2259, 1996
7. Conn SL, Moss TJ, Hoover M, et al: Treatment of poor-risk neuroblastoma patients with high-dose chemotherapy and autologous peripheral stem cell rescue. Bone Marrow Transplant 20:543-551, 1997
8. Haut PR, Cohn S, Morgan E, et al: Efficacy of autologous peripheral blood stem cell (PBSC) harvest and engraftment after ablative chemotherapy in pediatric patients. Biol Blood Marrow Transplant 4:38-42, 1998
9. Diaz MA, Villa M, Madero L, et al: Analysis of engraftment kinetics in pediatric patients undergoing autologous PBPC transplantation. J Hematother 7:367-373, 1998
10. Civin CI, Trischmann T, Kadan NS, et al: Highly purified CD34-positive cells reconstitute hematopoiesis. J Clin Oncol 14:2224-2233, 1996
11. Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466-1477, 1993
12. Sugrue MW, Hutcheson CE, Fisk DD, et al: The effect of overnight storage of leukapheresis stem cell products on cell viability, recovery and cost. J Hematother 7:431-436, 1998
13. Shpall EJ, Jones RB, Bearman SI, et al: Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: Influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 12:28-36, 1994
14. Bearman SI: The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 85:3005-3020, 1995
15. Kaplan FL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 52:457-481, 1958
16. Moss TJ, Reynolds CP, Sather HN, et al: Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med 324:219-226, 1991
17. Rogers DW, Treleaven JG, Kemshead JT, et al: Monoclonal antibodies for detecting bone marrow invasion by neuroblastoma. J Clin Pathol 42:422-426, 1989
18. Gorlin JG, Humphries D, Kent P, et al: Pediatric large volume peripheral blood progenitor cell collections from patients under 25 kg: A primer. J Clin Apheresis 11:195-203, 1996
19. Gorlin JB, Vamvakes EC, Cooke E, et al: Large-volume leukapheresis in pediatric patients: Processing more blood diminishes the apparent magnitude of intra-apheresis recruitment. Transfusion 36:879-885, 1996
20. Richardson PG, Elias AD. Krishnan A, et al: Treatment of severe veno-occlusive disease with defibrotide: Compassionate use results in response without significant toxicity in a high-risk population. Blood 92:737-744, 1998
21. Matthay KK, O'Leary MC, Ramsay NK, et al: Role of myeloablative therapy in improved outcome for high risk neuroblastoma: Review of recent Children's Cancer Group results. Eur J Cancer 31A:572-575, 1995
22. Stram DO, Matthay KK, O'Leary M, et al: Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: A report of two concurrent Children's Cancer Group studies. J Clin Oncol 14:2417-2426, 1996
23. Stram DO, Matthay KK, O'Leary M, et al: Myeloablative chemoradiotherapy versus continued chemotherapy for high risk neuroblastoma. Prog Clin Biol Res 385:287-291, 1994
24. Matthay KK, Harris R, Reynolds CP, et al: Improved event-free survival (EFS) for autologous bone marrow transplantation (ABMT) vs chemotherapy in neuroblastoma: A phase III randomized Children's Cancer Group (CCG) study. Proc Am Soc Clin Oncol 17:525a, 1998 (abstr 2018)
25. Ayash LJ, Elias A, Schwartz G, et al: Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: No improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. J Clin Oncol 14:2984-2992, 1996
26. Bitran JD, Samuels B, Klein L, et al: Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer. Bone Marrow Transplant 17:157-162, 1996
27. Barlogie B, Jagannath S, Vesole DH, et al: Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89:789-793, 1997
28. Meisenberg BR, Miller WE, McMillan R: Mobilized peripheral blood progenitor cells (PBPC) in support of tandem cycles of high-dose chemotherapy (HDC). Bone Marrow Transplant 18:1087-1093, 1996
29. Kajiume T, Kawano Y, Takaue Y, et al: New consecutive high-dose chemotherapy modality with fractionated blood stem cell support in the treatment of high-risk pediatric solid tumors: A feasibility study. Bone Marrow Transplant 21:147-151, 1998
30. Ladenstein R, Philip T, Lasset C, et al: Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: A report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 16:953-965, 1998
31. Rill DR, Santana VM, Roberts WM, et al: Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 84:380-383, 1994
32. Voigt A, Hafer R, Gruhn B, et al: Expression of CD34 and other haematopoietic antigens on neuroblastoma cells: Consequences for autologous bone marrow and peripheral blood stem cell transplantation. J Neuroimmunol 78:117-126, 1997
33. Greenfield D, Franklin WA, Tyson RW, et al: CD34 expression on pediatric solid tumors. Proc Am Soc Pediatr Hematol Oncol, 1996
34. Lode HN, Handgretinger R, Schuermann U, et al: Detection of neuroblastoma cells in CD34+ selected peripheral stem cells using a combination of tyrosine hydroxylase nested RT-PCR and anti-ganglioside GD2 immunocytochemistry. Eur J Cancer 33:2024-2030, 1997
35. Tchirkov A, Kanold J, Giollant M, et al: Molecular monitoring of rumor cell contamination in leukapheresis products from stage IV neuroblastoma patients before and after positive CD34 selection. Med Pediatr Oncol 30:228-232, 1998
36. Handgretinger R, Greil J, Schurmann U, et al: Positive selection and transplantation of peripheral CD34+ progenitor cells: Feasibility and purging efficacy in pediatric patients with neuroblastoma. J Hematother 6:235-242, 1997
37. Kanold J, Yakouben K, Tchirkov A, et al: Long-term follow-up after CD34+ cell transplantation in children with neuroblastoma. Blood 92:445a, 1998 (abstr 1842)